EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access

Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177 Lu-PSMA-617: A Retrospective Multicenter Cohort Study

Ruben Raychaudhuri iD, George Mo, Abuzar Moradi Tuchayi, Laura Graham iD, Roman Gulati iD, Colin C Pritchard iD, Michael C Haffner iD, Todd Yezefski iD, Jessica E Hawley iD, Heather H Cheng iD, Evan Y Yu iD, Petros Grivas iD und 6 weitere

JCO Precision Oncology · 2024

DOI: 10.1200/po.23.00634 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Ruben Raychaudhuri und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, University of Washington, Seattle, WA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Dipeptides. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE While 177 Lu-PSMA-617 (LuPSMA) is an effective therapy for many patients with metastatic castration-resistant prostate cancer (mCRPC), biomarkers associated with outcomes are not well defined. We hypothesized that prostate cancer mutational profile may associate with clinical activity of LuPSMA. We devised a study to evaluate associations between mCRPC mutational profile with LuPSMA clinical outcomes. METHODS This was a multicenter retrospective analysis of patients with mCRPC with next-generation sequencing (NGS) who received LuPSMA. PSA 50 response (ie, ≥50% decline in prostate-specific antigen [PSA]) rate, PSA progression free survival (PSA PFS), and overall survival (OS) were compared between genetically defined subgroups. RESULTS One hundred twenty-six patients with NGS results who received at least one cycle of LuPSMA were identified. The median age was 73 (IQR, 68-78) years, 124 (98.4%) received ≥1 prior androgen receptor-signaling inhibitor, and 121 (96%) received ≥1 taxane-based chemotherapy regimen. Fifty-eight (46%) patients with a DNA damage repair gene mutation (DNA damage response group) and 59 (46.8%) with a mutation in TP53, RB1, or PTEN tumor suppressor genes (TSG group) were identified. After adjusting for relevant confounders, the presence of ≥1 TSG mutation was associated with shorter PSA PFS (hazard ratio [HR], 1.93 [95% CI, 1.05 to 3.54]; P = .034) and OS (HR, 2.65 [95% CI, 1.15 to 6.11]; P = .023). There was improved OS favoring the DNA damage response group (HR, 0.37 [95% CI, 0.14 to 0.97]; P = .044) on multivariable analysis. Univariate analysis of patients with ATM mutations had significantly higher rates of PSA 50 response, PSA PFS, and OS. CONCLUSION Outcomes on LuPSMA varied on the basis of mutational profile. Prospective studies to define the clinical activity of LuPSMA in predefined genomic subgroups are justified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumDipeptidesHumansMaleRetrospective StudiesAgedHeterocyclic Compounds, 1-RingProstate-Specific AntigenAntigens, SurfaceCohort StudiesGlutamate Carboxypeptidase II

Substanzen

LutetiumDipeptidesPluvictoHeterocyclic Compounds, 1-RingProstate-Specific AntigenAntigens, SurfaceGlutamate Carboxypeptidase IIFOLH1 protein, human

Autor:innen und Institutionen

  • Division of Hematology and Oncology, University of Washington, Seattle, WA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA.
  • University of Colorado Medical Center, Aurora, CO.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.
  • Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA.

ORCID-Profile: Ruben Raychaudhuri, Laura Graham, Roman Gulati, Colin C Pritchard, Michael C Haffner, Todd Yezefski, Jessica E Hawley, Heather H Cheng, Evan Y Yu, Petros Grivas, Robert B Montgomery, Peter S Nelson, Delphine L Chen, Thomas Hope, Amir Iravani, Michael T Schweizer

Förderung

  • NCI NIH HHS

Zitieren

APA

Raychaudhuri, R., Mo, G., Tuchayi, A. M., Graham, L., Gulati, R., Pritchard, C. C., Haffner, M. C., Yezefski, T., Hawley, J. E., Cheng, H. H., Yu, E. Y., Grivas, P., Montgomery, R. B., Nelson, P. S., Chen, D. L., Hope, T., Iravani, A., & Schweizer, M. T. (2024). Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177 Lu-PSMA-617: A Retrospective Multicenter Cohort Study. JCO Precision Oncology. https://doi.org/10.1200/po.23.00634

Vancouver

Raychaudhuri R, Mo G, Tuchayi AM, Graham L, Gulati R, Pritchard CC, et al. Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177 Lu-PSMA-617: A Retrospective Multicenter Cohort Study. JCO Precision Oncology. 2024. doi:10.1200/po.23.00634

BibTeX
@article{Raychaudhuri2024,
  author = {Raychaudhuri, Ruben and Mo, George and Tuchayi, Abuzar Moradi and Graham, Laura and Gulati, Roman and Pritchard, Colin C and Haffner, Michael C and Yezefski, Todd and Hawley, Jessica E and Cheng, Heather H and Yu, Evan Y and Grivas, Petros and Montgomery, Robert B and Nelson, Peter S and Chen, Delphine L and Hope, Thomas and Iravani, Amir and Schweizer, Michael T},
  title = {Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177 Lu-PSMA-617: A Retrospective Multicenter Cohort Study},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.23.00634}
}
Kostenlos starten →